AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 05/19/20

With earnings season in the rear-view mirror for the specialty pharmaceutical sector, J.P. Morgan is updating its positioning on the sector as the COVID-19 pandemic marches on - reiterating its favorites in the area and issuing downgrades to a couple of companies facing challenges. More ne...

Image source: The Motley Fool. Amneal Pharmaceuticals, Inc.   (NYSE: AMRX) Q1 2020 Earnings Call May 11, 2020 , 8:30 a.m. ET Operator Continue reading

Amneal Pharmaceuticals Inc. (AMRX) Q1 2020 Earnings Conference Call May 11, 2020 08:30 AM ET Company Participants Tasos Konidaris - SVP and CFO Chirag Patel - Co CEO and President Chintu Patel - Co CEO Conference Call Participants Greg Gilbert - SunTrust Randall Stanicky ...

Cellect Biotechnology (NASDAQ: APOP ) +126%  on publication of ApoGraft data ahead of clinical trial. More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., AMC Entertainment Holdings, Inc., Stocks on the move, , Read more ...

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...

Amneal Pharmaceuticals ( AMRX ) Q1 results : More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Amneal Pharmaceuticals (NYSE: AMRX ): Q1 Non-GAAP EPS of $0.20 beats by $0.11 ; GAAP EPS of $0.78 beats by $0.75 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

‒ Q1 2020 Net Revenue of $ 499 million; GAAP Net Income of $115 million; Diluted Earnings per Share of $0.78 ‒ ‒ Q1 2020 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $134 million; Adjusted Diluted EPS (1) of $0.20 ‒ ‒ ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2020 financial results on Monday, May 11, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on M...

In a statement , the FDA is cautioning against the use of malaria meds chloroquine and hydroxychloroquine outside of the hospital setting for the treatment of COVID-19 due to the risk of adverse heart rhythm side effects. More news on: Tekla World Healthcare Fund, BlackRock Health Science...